We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly
Read MoreHide Full Article
Shares of ProQR Therapeutics N.V. (PRQR - Free Report) were up 63.6% on Thursday after the company announced that it expanded its current licensing and collaboration agreement with pharma giant Eli Lilly (LLY - Free Report) for the development and commercialization of new genetic medicines.
Last September, ProQR entered a licensing agreement with Eli Lilly for ProQR’s proprietary Axiomer RNA base-editing platform.
The ProQR stock has plunged 66.3% so far this year compared with the industry’s decline of 19.3%.
Image Source: Zacks Investment Research
Per the terms of the latest expanded agreement, PRQR is eligible to receive $75 million, comprising upfront and an equity investment from LLY.
Eli Lilly will get access to additional targets in the central nervous system and peripheral nervous system with ProQR’s Axiomer platform. It will also have the right to exercise an option to further expand the partnership for a consideration of $50 million. Eli Lilly may provide ProQR access to its proprietary delivery technology for its wholly-owned pipeline.
Based on the actual deal entered in September 2021 and the expanded agreement today, ProQR is entitled to receive up to $3.75 billion in research, development/commercialization milestones from Eli Lilly.
PRQR will also likely receive tiered royalties of up to a mid-single-digit percentage on net product sales if a product is approved and commercialized from the above collaboration.
With the expanded collaboration deal, the companies are looking to explore more applications of the Axiomer platform to unveil innovative treatments for people living with diseases that have a high unmet medical need.
The partnership continues to leverage ProQR’s Axiomer RNA editing technology platform with Eli Lilly’s expertise in RNA therapeutics.
Loss per share estimates for ASLAN Pharmaceuticals have narrowed 7.7% for 2022 and 7.4% for 2023 in the past 60 days.
Earnings of ASLAN Pharmaceuticals surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. ASLN witnessed an earnings surprise of 1.64% on average.
Loss per share estimates for Immunocore have narrowed 56.8% for 2022 and 58.5% for 2023 in the past 60 days.
Earnings of Immunocore surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. IMCR witnessed an earnings surprise of 68.34% on average.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly
Shares of ProQR Therapeutics N.V. (PRQR - Free Report) were up 63.6% on Thursday after the company announced that it expanded its current licensing and collaboration agreement with pharma giant Eli Lilly (LLY - Free Report) for the development and commercialization of new genetic medicines.
Last September, ProQR entered a licensing agreement with Eli Lilly for ProQR’s proprietary Axiomer RNA base-editing platform.
The ProQR stock has plunged 66.3% so far this year compared with the industry’s decline of 19.3%.
Image Source: Zacks Investment Research
Per the terms of the latest expanded agreement, PRQR is eligible to receive $75 million, comprising upfront and an equity investment from LLY.
Eli Lilly will get access to additional targets in the central nervous system and peripheral nervous system with ProQR’s Axiomer platform. It will also have the right to exercise an option to further expand the partnership for a consideration of $50 million. Eli Lilly may provide ProQR access to its proprietary delivery technology for its wholly-owned pipeline.
Based on the actual deal entered in September 2021 and the expanded agreement today, ProQR is entitled to receive up to $3.75 billion in research, development/commercialization milestones from Eli Lilly.
PRQR will also likely receive tiered royalties of up to a mid-single-digit percentage on net product sales if a product is approved and commercialized from the above collaboration.
With the expanded collaboration deal, the companies are looking to explore more applications of the Axiomer platform to unveil innovative treatments for people living with diseases that have a high unmet medical need.
The partnership continues to leverage ProQR’s Axiomer RNA editing technology platform with Eli Lilly’s expertise in RNA therapeutics.
Zacks Rank & Stocks to Consider
ProQR currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are ASLAN Pharmaceuticals Limited (ASLN - Free Report) and Immunocore Holdings plc (IMCR - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Loss per share estimates for ASLAN Pharmaceuticals have narrowed 7.7% for 2022 and 7.4% for 2023 in the past 60 days.
Earnings of ASLAN Pharmaceuticals surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. ASLN witnessed an earnings surprise of 1.64% on average.
Loss per share estimates for Immunocore have narrowed 56.8% for 2022 and 58.5% for 2023 in the past 60 days.
Earnings of Immunocore surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. IMCR witnessed an earnings surprise of 68.34% on average.